Founded Year

2013

Stage

Series C - II | Alive

Total Raised

$124.7M

Last Raised

$30M | 5 mos ago

Mosaic Score

+120 points in the past 30 days

What is a Mosaic Score?
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

About Eko

Eko creates digital health solutions including AI-enabled stethoscopes, patient and provider software, and AI-powered analytics that enable doctors, nurses, researchers, and entire health systems to change care for the heart.

Eko Headquarter Location

1212 Broadway Suite 100

Oakland, California, 94612,

United States

844-356-3384

Eko's Product Videos

ESPs containing Eko

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTHMARKET STRENGTHLEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare / Healthcare Providers Tech

These companies facilitate the electronic collection and transmission of patient data outside of a healthcare setting. Solutions include wearable devices as well as software and services that can often be tailored to specific conditions, such as diabetes, congestive heart failure, and hypertension.

Eko named as Leader among 11 other companies, including Glooko, Huma, and TytoCare.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Eko's Products & Differentiation

See Eko's products and how their products differentiate from alternatives and competitors

  • Transform the stethoscope you already own and enhance auscultation through amplification, active noise cancellation, wireless listening, and Eko software.

    Differentiation

    Only digital stethoscope attachment on the market that provides active noise cancellation, amplification, and access to our decision support tools 

  • We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

Expert Collections containing Eko

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Eko is included in 12 Expert Collections, including Digital Health.

D

Digital Health

13,197 items

Startups recreating how healthcare is delivered

A

Artificial Intelligence

9,093 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

V

Value-Based Care & Population Health

1,049 items

The VBC & Population Health collection includes companies that enable and deliver care models that address the health needs for defining populations along the continuum of care, including in the community setting, through participation, engagement, and targeted interventions.

M

Medical Devices

11,967 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

A

AI 100

100 items

The winners of the 4th annual CB Insights AI 100.

C

Conference Exhibitors

5,302 items

Eko Patents

Eko has filed 3 patents.

The 3 most popular patent topics include:

  • Wireless networking
  • Audio codecs
  • Audio engineering
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/10/2017

3/16/2021

Cardiac arrhythmia, Sensors, Cardiology, Cardiac electrophysiology, Wireless networking

Grant

Application Date

3/10/2017

Grant Date

3/16/2021

Title

Related Topics

Cardiac arrhythmia, Sensors, Cardiology, Cardiac electrophysiology, Wireless networking

Status

Grant

Latest Eko News

Candel Therapeutics : Appoints Three New Members to its Board of Directors - Form 8-K

Aug 1, 2022

08/01/2022 | 06:25am EDT Message : • Gary Nabel, MD, PhD, Chief Innovation Officer of OPKO and Chief Executive Officer, ModeX Therapeutics, Inc., an OPKO Health company • • Renee Gaeta, Chief Financial Officer of Eko Devices NEEDHAM, Mass., August 1, 2022 (GLOBE NEWSWIRE) - Candel Therapeutics, Inc. (Candel or the Company)(Nasdaq: CADL), a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies, today announced the appointment of three new members to its Board: Gary Nabel, MD, PhD, renowned virologist and immunologist; Joseph C. Papa, prominent business leader; and Renee Gaeta, strategic financial expert, effective August 8, 2022. These new members replace current Board members: Alan E. Smith, PhD, Shaan Ghandi, MD, D.Phil, and Udi Meirav, PhD, maintaining Candel's nine-seat board. "We are pleased to welcome Renee, Gary, and Joseph, preeminent leaders in their respective fields, as new directors to the Candel Board," said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer (CEO) at Candel. "They bring a wealth of experience in biopharmaceutical industry, science, and value creation. Each of them will offer unique and valuable perspectives that we confidently believe will add to our growth, strengthening our foundation as we pursue highly differentiated oncolytic viral immunotherapies for patients with cancer." Dr. Gary Nabel, a renowned virologist and immunologist, currently serves as Chief Innovation Officer of OPKO and President/CEO of ModeX Therapeutics that merged as a subsidiary of OPKO Health in May 2022. Before this, he served as Chief Scientific Officer and Senior Vice President at Sanofi, where he oversaw the Breakthrough Laboratory that worked to create the first trispecific antibodies for HIV, cancer immunotherapies, and novel vaccines. Prior to Sanofi, Dr. Nabel spearheaded progressive research on HIV, influenza, SARS, Ebola, Chikungunya, and Epstein-Barr virus while he served as founding director at the NIH's Vaccine Center for more than a decade. His honors include being elected to the Institute of Medicine for the National Academy of Science and the Amgen Scientific Achievement Award from the American Society for Biochemistry and Molecular Biology, following his countless accomplishments across virology, immunology, gene therapy, and molecular biology. Joseph C. Papa has more than 35 years of experience in the pharmaceutical, health care and specialty pharmaceutical industries, including more than 20 years of branded prescription drug experience. In July 2022, he stepped down as chair of Bausch + Lomb's Board and will remain CEO until his successor is appointed. Prior to Bausch + Lomb, Mr. Papa had led various organizations, including Bausch Health formerly known as Valeant Pharmaceuticals, Perrigo, and the Cardinal Health PTS business, as Chairman and CEO separately during the period of two decades. In 2014, he was ranked 47 on Harvard Business Review's "Best Performing CEOs in the World". His track record for leadership continued as he served as President and Chief Operating Officer for Watson Pharmaceuticals (2001-2004), President of Global Country Operations for Pharmacia's North American business (2000-2001), and President of Searle's US Operations (1997-2000). During his 15-year career at Novartis Pharmaceuticals, he and his teams successfully launched the pharmaceutical products Lotrel®, Divovan®, and Celebrex®. Mr. Papa currently serves on the Board of Prometheus Biosciences and had been a previous member of the Boards for the UConn Foundation and Smith & Nephew. Renee Gaeta currently serves as Chief Financial Officer (CFO) at Eko Devices, a privately held cardiopulmonary digital health company. Before joining Eko, she served as CFO and member of the executive team at Establishment Labs Holdings, Inc. There, she successfully led the organization to an Initial Public Offering (IPO) and through a significant growth and value creation stage. Mrs. Gaeta has played integral roles across the financial sector including during her role as Vice President, Corporate Controller, and executive team member at publicly traded company, Sientra, Inc., where she guided the company during its pre-IPO period, as well as continued financing following their IPO. Before leading the finance department of Sientra, she exceled in multiple roles within KPMG over a decade with her most recent role having been Advisory Director in the Transactions and Restructuring Group. Mrs. Gaeta currently serves on the Board of SeaSpine Holdings Corporation as Audit Committee Chair and is a Certified Public Accountant in the State of California. Paul B. Manning, Chairman of Candel and Chairman and CEO of PBM Capital Investments, said, "Innovation is central to Candel and we welcome the novel and diverse perspectives that Gary, Joe, and Renee will bring. They join the Board at an exciting time, and we look forward to working with them to further grow the company and develop life-improving oncolytic viral immunotherapies." Dr. Tak concluded, "On behalf of Candel, I would personally like to thank Alan, Shaan and Udi for their commitment to our mission over the years and for their support that has helped us with the wonderful progress we have made as an organization. We are grateful for their many contributions." About Candel Therapeutics Candel is a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies. Candel's engineered viruses are designed to induce immunogenic cell death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection. Candel has established two oncolytic viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and CAN-3110 is the lead product candidate from the HSV platform. New discovery programs are based on the enLIGHTEN™ HSV platform. For more information about Candel, visit www.candeltx.com. Forward-Looking Statements This press release includes certain disclosures that contain "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, including key data readout milestones and indications; expectations regarding the therapeutic benefit of its programs; and expectations regarding cash runway and expenditures. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company's programs; the Company's ability to efficiently discover and develop product candidates; the Company's ability to obtain and maintain regulatory approval of product candidates; the Company's ability to maintain its intellectual property; the implementation of the Company's business model, and strategic plans for the Company's business and product candidates, and other risks identified in the Company's SEC filings, including the Company's Quarterly Report on Form 10-Q filed on May 12, 2022, and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Media Contact

Eko Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Eko Rank

  • When was Eko founded?

    Eko was founded in 2013.

  • Where is Eko's headquarters?

    Eko's headquarters is located at 1212 Broadway, Oakland.

  • What is Eko's latest funding round?

    Eko's latest funding round is Series C - II.

  • How much did Eko raise?

    Eko raised a total of $124.7M.

  • Who are the investors of Eko?

    Investors of Eko include MedTech Innovator, Artis Ventures, 3M Ventures, NTT Venture Capital, DigiTx Partners and 15 more.

  • Who are Eko's competitors?

    Competitors of Eko include SEERS Technology, Strados Labs, Vayyar, Vesta Healthcare, Biofourmis, EarLens, Optimize Health, Cardiac Insight, Huma, VivoSense and 77 more.

  • What products does Eko offer?

    Eko's products include , undefined and 6 more.

You May Also Like

AliveCor Logo
AliveCor

AliveCor focuses on the creation of FDA-cleared machine learning techniques to enable proactive heart care and is recognized around the world for transforming cardiac care. The FDA-cleared KardiaMobile is a clinically validated mobile EKG solution on the market. It is recommended by cardiologists and used by people worldwide for accurate EKG recordings. KardiaMobile, and KardiaBand, when paired with the Kardia app provide instant analysis for detecting atrial fibrillation (AF) and normal sinus rhythm in an EKG.

TytoCare Logo
TytoCare

TytoCare connects people to clinicians to provide virtual home examinations and diagnosis solutions. TytoCare's solutions are designed to enable a comprehensive medical exam with clinicians, from any location.

Biofourmis Logo
Biofourmis

Biofourmis discovers, develops, and delivers clinically-validated, software-based therapeutics to provide better outcomes for patients, advanced tools for clinicians to deliver personalized care, technology for pharmaceutical companies to demonstrate value, and cost-effective solutions for payers. Biofourmis has built Biovitals, a personalized, AI-powered health analytics platform that predicts clinical exacerbation in advance of a critical event, which is the backbone of its digital therapeutics product pipeline across multiple therapeutic areas, including heart failure, oncology, acute coronary syndrome, COPD, and chronic pain. The company was founded in 2015 and is based in Boston, Massachusetts.

Babyscripts Logo
Babyscripts

Babyscripts is a doctor-delivered, digital health tool for prenatal care, enhancing the doctor/patient relationship outside of the clinic's walls during routine, low-risk pregnancy care and providing remote monitoring to better identify high-risk pregnancies.

Withings Logo
Withings

Withings creates smart products and apps to help people across the world take care of their health and well-being. By extending the capabilities of an object through network resources, Withings provides access to computing and storage facility at no extra cost, turning objects into smart connected devices.

VitalConnect Logo
VitalConnect

VitalConnect currently markets the VitalConnect Platform that includes two wearable biosensors combined with mobile and cloud-based software and analytics. HealthPatch MD and VitalPatch biosensors are wireless, adhesive patches that continuously monitor and record single-lead ECG, heart rate, heart rate variability, respiratory rate, skin temperature, posture, step count, and fall detection with clinical accuracy. Through the VitalConnect Platform, care teams receive accurate data and notifications to make health decisions and enable timely interventions.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.